|
|
 |
|
Viewing report
|
|
|
|
Zydus Cadila Generics Company Intelligence Report
Espicom Business Intelligence Ltd, Jan 2011, Pages: 12
Cadila was founded in 1952, and was restructured in 1992 to become the Zydus Cadila Group. Cadila Healthcare, the Group's flagship company, was launched as an IPO in February 2000. The Zydus Group is aiming to become one of the top three healthcare companies in India and a global player. It has made forays into the US and EU markets, and other markets, such as Brazil, South Africa and Algeria. It started selling in Japan in 2007.
In July 2003, Zydus signed an agreement to acquire Alpharma SAS France, which it has renamed Zydus France. The acquisition gave the company an established distribution network and a pipeline of 109 generic registrations.
Zydus gained its first US ANDA approval, for atenolol tablets, in January 2005. The company has continued to push its presence in the US market since.
In May 2008, Zydus purchased the Spanish firm, Laboratorios Combix. The purchase enabled Zydus’ entry into the Spanish generics market. In November 2008, the firm acquired Etna Biotech in Italy, giving it a development platform for new vaccines.
In FY2009/10, ended 31st March 2010, Zydus reported consolidated gross sales worth Rs36,142 million (US$763.0 million). This was an increase of 23.9% over the prior year. Net profit increased by 66.6%, reaching Rs5,051 million (US$106.6 million).
At the end of 2009, the South African firm, Simayla, became wholly-owned by Zydus. Zydus had gained a 70% majority stake in Simayla in 2008, and acquired the remaining 30% in 2009.
In May 2010, Zydus and Abbott announced that they had entered into a strategic agreement focusing on the emerging markets. Abbott will licence 24 of Zydus' branded generics in 15 key emerging markets; the agreement includes an option for a further 40 products to be included.
Executive Summary
Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Customers who bought this item also bought
Zydus Cadila Healthcare Limited - Product Pipeline Review - H2 2011
Zydus Cadila Healthcare Limited - Product Pipeline Review - Q4 2010
Aurobindo Generics Company Intelligence Report
Wockhardt Generics Company Intelligence Report
Dr Reddy's Laboratories Generics Company Intelligence Report
Sun Pharmaceuticals Generics Company Intelligence Report
Hospira Generics Company Intelligence Report
Sanofi-Aventis Generics Company Intelligence Report
Lupin Generics Company Intelligence Report
Watson Pharmaceuticals Generics Company Intelligence Report
|
|
|
|
